Microbot Medical (NASDAQ:MBOT) Stock Passes Above 200 Day Moving Average - Time to Sell?

Microbot Medical Inc. (NASDAQ:MBOT - Get Free Report)'s stock price passed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $1.50 and traded as high as $2.70. Microbot Medical shares last traded at $2.62, with a volume of 1,092,500 shares changing hands.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a "buy" rating and set a $9.00 price target on shares of Microbot Medical in a research report on Thursday, April 10th.

Microbot Medical Price Performance

The firm has a market capitalization of $87.03 million, a P/E ratio of -3.13 and a beta of 1.40. The company's 50 day moving average price is $1.81 and its 200 day moving average price is $1.53.

Microbot Medical (NASDAQ:MBOT - Get Free Report) last announced its quarterly earnings data on Wednesday, March 26th. The biotechnology company reported ($0.20) EPS for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.02). On average, research analysts anticipate that Microbot Medical Inc. will post -0.71 EPS for the current fiscal year.

Institutional Trading of Microbot Medical

A hedge fund recently bought a new stake in Microbot Medical stock. Renaissance Technologies LLC purchased a new position in shares of Microbot Medical Inc. (NASDAQ:MBOT - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 105,658 shares of the biotechnology company's stock, valued at approximately $118,000. Renaissance Technologies LLC owned about 0.52% of Microbot Medical at the end of the most recent reporting period. Institutional investors and hedge funds own 16.30% of the company's stock.

About Microbot Medical

Microbot Medical Inc, a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces.